Clinical Trial

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer. This is a phase 2 study to deliver focal radiation with pulsed systemic therapy of Abiraterone, ADT and Lynparza (olaparib) in men with castration sensitive oligometastatic prostate cancer.
Protocol Amendment History 1 change
minor Completion pushed: 2026-05 -> 2027-05 2026-07-14
Trial Details
NCT Number NCT04748042
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
Enrollment 21 participants
Start Date 2021-05-28
Primary Completion 2026-05-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-13